Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 123

1.

CAR T Cells with Enhanced Sensitivity to B Cell Maturation Antigen for the Targeting of B Cell Non-Hodgkin's Lymphoma and Multiple Myeloma.

Bluhm J, Kieback E, Marino SF, Oden F, Westermann J, Chmielewski M, Abken H, Uckert W, Höpken UE, Rehm A.

Mol Ther. 2018 Aug 1;26(8):1906-1920. doi: 10.1016/j.ymthe.2018.06.012. Epub 2018 Jun 18.

2.

Efficient Non-Viral T-Cell Engineering by Sleeping Beauty Minicircles Diminishing DNA Toxicity and miRNAs Silencing the Endogenous T-Cell Receptors.

Clauss J, Obenaus M, Miskey C, Ivics Z, Izsvák Z, Uckert W, Bunse M.

Hum Gene Ther. 2018 May;29(5):569-584. doi: 10.1089/hum.2017.136.

PMID:
29562762
3.

Distinguishing features of microglia- and monocyte-derived macrophages after stroke.

Kronenberg G, Uhlemann R, Richter N, Klempin F, Wegner S, Staerck L, Wolf S, Uckert W, Kettenmann H, Endres M, Gertz K.

Acta Neuropathol. 2018 Apr;135(4):551-568. doi: 10.1007/s00401-017-1795-6. Epub 2017 Dec 16.

PMID:
29249001
4.

Unbiased Identification of T-Cell Receptors Targeting Immunodominant Peptide-MHC Complexes for T-Cell Receptor Immunotherapy.

Lorenz FKM, Ellinger C, Kieback E, Wilde S, Lietz M, Schendel DJ, Uckert W.

Hum Gene Ther. 2017 Dec;28(12):1158-1168. doi: 10.1089/hum.2017.122. Epub 2017 Sep 26.

5.

Isolation and functional characterization of hepatitis B virus-specific T-cell receptors as new tools for experimental and clinical use.

Wisskirchen K, Metzger K, Schreiber S, Asen T, Weigand L, Dargel C, Witter K, Kieback E, Sprinzl MF, Uckert W, Schiemann M, Busch DH, Krackhardt AM, Protzer U.

PLoS One. 2017 Aug 8;12(8):e0182936. doi: 10.1371/journal.pone.0182936. eCollection 2017.

6.

Chimeric PD-1:28 Receptor Upgrades Low-Avidity T cells and Restores Effector Function of Tumor-Infiltrating Lymphocytes for Adoptive Cell Therapy.

Schlenker R, Olguín-Contreras LF, Leisegang M, Schnappinger J, Disovic A, Rühland S, Nelson PJ, Leonhardt H, Harz H, Wilde S, Schendel DJ, Uckert W, Willimsky G, Noessner E.

Cancer Res. 2017 Jul 1;77(13):3577-3590. doi: 10.1158/0008-5472.CAN-16-1922. Epub 2017 May 22.

7.

Tumour ischaemia by interferon-γ resembles physiological blood vessel regression.

Kammertoens T, Friese C, Arina A, Idel C, Briesemeister D, Rothe M, Ivanov A, Szymborska A, Patone G, Kunz S, Sommermeyer D, Engels B, Leisegang M, Textor A, Fehling HJ, Fruttiger M, Lohoff M, Herrmann A, Yu H, Weichselbaum R, Uckert W, Hübner N, Gerhardt H, Beule D, Schreiber H, Blankenstein T.

Nature. 2017 May 4;545(7652):98-102. doi: 10.1038/nature22311. Epub 2017 Apr 26.

8.

Domain-swapped T cell receptors improve the safety of TCR gene therapy.

Bethune MT, Gee MH, Bunse M, Lee MS, Gschweng EH, Pagadala MS, Zhou J, Cheng D, Heath JR, Kohn DB, Kuhns MS, Uckert W, Baltimore D.

Elife. 2016 Nov 8;5. pii: e19095. doi: 10.7554/eLife.19095.

9.

In vivo transduction of primitive mobilized hematopoietic stem cells after intravenous injection of integrating adenovirus vectors.

Richter M, Saydaminova K, Yumul R, Krishnan R, Liu J, Nagy EE, Singh M, Izsvák Z, Cattaneo R, Uckert W, Palmer D, Ng P, Haworth KG, Kiem HP, Ehrhardt A, Papayannopoulou T, Lieber A.

Blood. 2016 Nov 3;128(18):2206-2217. Epub 2016 Aug 23.

10.

Transgenic antigen-specific, HLA-A*02:01-allo-restricted cytotoxic T cells recognize tumor-associated target antigen STEAP1 with high specificity.

Schirmer D, Grünewald TG, Klar R, Schmidt O, Wohlleber D, Rubío RA, Uckert W, Thiel U, Bohne F, Busch DH, Krackhardt AM, Burdach S, Richter GH.

Oncoimmunology. 2016 Apr 25;5(6):e1175795. doi: 10.1080/2162402X.2016.1175795. eCollection 2016 Jun.

11.

Targeting B-cell neoplasia with T-cell receptors recognizing a CD20-derived peptide on patient-specific HLA.

Mensali N, Ying F, Sheng VO, Yang W, Walseng E, Kumari S, Fallang LE, Kolstad A, Uckert W, Malmberg KJ, Wälchli S, Olweus J.

Oncoimmunology. 2016 Feb 18;5(5):e1138199. doi: 10.1080/2162402X.2016.1138199. eCollection 2016 May.

12.

ERK1 as a Therapeutic Target for Dendritic Cell Vaccination against High-Grade Gliomas.

Ku MC, Edes I, Bendix I, Pohlmann A, Waiczies H, Prozorovski T, Günther M, Martin C, Pagès G, Wolf SA, Kettenmann H, Uckert W, Niendorf T, Waiczies S.

Mol Cancer Ther. 2016 Aug;15(8):1975-87. doi: 10.1158/1535-7163.MCT-15-0850. Epub 2016 Jun 2.

13.

Thymus-Derived Regulatory T Cells Are Positively Selected on Natural Self-Antigen through Cognate Interactions of High Functional Avidity.

Kieback E, Hilgenberg E, Stervbo U, Lampropoulou V, Shen P, Bunse M, Jaimes Y, Boudinot P, Radbruch A, Klemm U, Kühl AA, Liblau R, Hoevelmeyer N, Anderton SM, Uckert W, Fillatreau S.

Immunity. 2016 May 17;44(5):1114-26. doi: 10.1016/j.immuni.2016.04.018.

14.

Proteasomes generate spliced epitopes by two different mechanisms and as efficiently as non-spliced epitopes.

Ebstein F, Textoris-Taube K, Keller C, Golnik R, Vigneron N, Van den Eynde BJ, Schuler-Thurner B, Schadendorf D, Lorenz FK, Uckert W, Urban S, Lehmann A, Albrecht-Koepke N, Janek K, Henklein P, Niewienda A, Kloetzel PM, Mishto M.

Sci Rep. 2016 Apr 6;6:24032. doi: 10.1038/srep24032.

15.

Targeting human melanoma neoantigens by T cell receptor gene therapy.

Leisegang M, Kammertoens T, Uckert W, Blankenstein T.

J Clin Invest. 2016 Mar 1;126(3):854-8. doi: 10.1172/JCI83465. Epub 2016 Jan 25.

16.

Genome-wide Profiling Reveals Remarkable Parallels Between Insertion Site Selection Properties of the MLV Retrovirus and the piggyBac Transposon in Primary Human CD4(+) T Cells.

Gogol-Döring A, Ammar I, Gupta S, Bunse M, Miskey C, Chen W, Uckert W, Schulz TF, Izsvák Z, Ivics Z.

Mol Ther. 2016 Mar;24(3):592-606. doi: 10.1038/mt.2016.11. Epub 2016 Jan 12.

17.

Eradication of Large Solid Tumors by Gene Therapy with a T-Cell Receptor Targeting a Single Cancer-Specific Point Mutation.

Leisegang M, Engels B, Schreiber K, Yew PY, Kiyotani K, Idel C, Arina A, Duraiswamy J, Weichselbaum RR, Uckert W, Nakamura Y, Schreiber H.

Clin Cancer Res. 2016 Jun 1;22(11):2734-43. doi: 10.1158/1078-0432.CCR-15-2361. Epub 2015 Dec 14.

18.

T Cells Engineered to Express a T-Cell Receptor Specific for Glypican-3 to Recognize and Kill Hepatoma Cells In Vitro and in Mice.

Dargel C, Bassani-Sternberg M, Hasreiter J, Zani F, Bockmann JH, Thiele F, Bohne F, Wisskirchen K, Wilde S, Sprinzl MF, Schendel DJ, Krackhardt AM, Uckert W, Wohlleber D, Schiemann M, Stemmer K, Heikenwälder M, Busch DH, Richter G, Mann M, Protzer U.

Gastroenterology. 2015 Oct;149(4):1042-52. doi: 10.1053/j.gastro.2015.05.055. Epub 2015 Jun 5.

PMID:
26052074
19.

Codon optimization of the human papillomavirus E7 oncogene induces a CD8+ T cell response to a cryptic epitope not harbored by wild-type E7.

Lorenz FK, Wilde S, Voigt K, Kieback E, Mosetter B, Schendel DJ, Uckert W.

PLoS One. 2015 Mar 23;10(3):e0121633. doi: 10.1371/journal.pone.0121633. eCollection 2015.

20.

Identification of human T-cell receptors with optimal affinity to cancer antigens using antigen-negative humanized mice.

Obenaus M, Leitão C, Leisegang M, Chen X, Gavvovidis I, van der Bruggen P, Uckert W, Schendel DJ, Blankenstein T.

Nat Biotechnol. 2015 Apr;33(4):402-7. doi: 10.1038/nbt.3147. Epub 2015 Mar 16.

PMID:
25774714
21.

Targeting cancer-specific mutations by T cell receptor gene therapy.

Blankenstein T, Leisegang M, Uckert W, Schreiber H.

Curr Opin Immunol. 2015 Apr;33:112-9. doi: 10.1016/j.coi.2015.02.005. Epub 2015 Feb 27. Review.

22.

CD8 T cell tolerance to a tumor-associated self-antigen is reversed by CD4 T cells engineered to express the same T cell receptor.

Ghorashian S, Veliça P, Chua I, McNicol AM, Carpenter B, Holler A, Nicholson E, Ahmadi M, Zech M, Xue SA, Uckert W, Morris E, Chakraverty R, Stauss HJ.

J Immunol. 2015 Feb 1;194(3):1080-9. doi: 10.4049/jimmunol.1401703. Epub 2014 Dec 24.

23.

IFN-γ regulates CD8+ memory T cell differentiation and survival in response to weak, but not strong, TCR signals.

Stoycheva D, Deiser K, Stärck L, Nishanth G, Schlüter D, Uckert W, Schüler T.

J Immunol. 2015 Jan 15;194(2):553-9. doi: 10.4049/jimmunol.1402058. Epub 2014 Dec 5.

24.

HEK293-based production platform for γ-retroviral (self-inactivating) vectors: application for safe and efficient transfer of COL7A1 cDNA.

Hennig K, Raasch L, Kolbe C, Weidner S, Leisegang M, Uckert W, Titeux M, Hovnanian A, Kuehlcke K, Loew R.

Hum Gene Ther Clin Dev. 2014 Dec;25(4):218-28. doi: 10.1089/humc.2014.083.

PMID:
25381930
25.

Manufacture of gene-modified human T-cells with a memory stem/central memory phenotype.

Gomez-Eerland R, Nuijen B, Heemskerk B, van Rooij N, van den Berg JH, Beijnen JH, Uckert W, Kvistborg P, Schumacher TN, Haanen JB, Jorritsma A.

Hum Gene Ther Methods. 2014 Oct;25(5):277-87. doi: 10.1089/hgtb.2014.004. Epub 2014 Sep 22.

26.

RNAi-mediated TCR knockdown prevents autoimmunity in mice caused by mixed TCR dimers following TCR gene transfer.

Bunse M, Bendle GM, Linnemann C, Bies L, Schulz S, Schumacher TN, Uckert W.

Mol Ther. 2014 Nov;22(11):1983-91. doi: 10.1038/mt.2014.142. Epub 2014 Jul 22.

27.

Misinitiation of intrathymic MART-1 transcription and biased TCR usage explain the high frequency of MART-1-specific T cells.

Pinto S, Sommermeyer D, Michel C, Wilde S, Schendel D, Uckert W, Blankenstein T, Kyewski B.

Eur J Immunol. 2014 Sep;44(9):2811-21. doi: 10.1002/eji.201444499. Epub 2014 Aug 18.

28.

Targeting high-grade B cell lymphoma with CD19-specific T cells.

Lehmann FM, Maurberger A, Feicht S, Helm F, Ladinig C, Kieback E, Uckert W, Kammertöns T, Kremmer E, Mautner J, Gerbitz A, Bornkamm GW.

Int J Cancer. 2014 Sep 1;135(5):1153-64. doi: 10.1002/ijc.28760. Epub 2014 Feb 20.

29.

Immunotherapy with TCR-redirected T cells: comparison of TCR-transduced and TCR-engineered hematopoietic stem cell-derived T cells.

Stärck L, Popp K, Pircher H, Uckert W.

J Immunol. 2014 Jan 1;192(1):206-13. doi: 10.4049/jimmunol.1202591. Epub 2013 Nov 29.

30.

TCR-engineered T cells: a model of inducible TCR expression to dissect the interrelationship between two TCRs.

Reuß S, Sebestyén Z, Heinz N, Loew R, Baum C, Debets R, Uckert W.

Eur J Immunol. 2014 Jan;44(1):265-74. doi: 10.1002/eji.201343591. Epub 2013 Oct 20.

31.

Plasticity in the contribution of T cell receptor variable region residues to binding of peptide-HLA-A2 complexes.

Smith SN, Sommermeyer D, Piepenbrink KH, Blevins SJ, Bernhard H, Uckert W, Baker BM, Kranz DM.

J Mol Biol. 2013 Nov 15;425(22):4496-507. doi: 10.1016/j.jmb.2013.08.007. Epub 2013 Aug 14.

32.

TCR-ligand koff rate correlates with the protective capacity of antigen-specific CD8+ T cells for adoptive transfer.

Nauerth M, Weißbrich B, Knall R, Franz T, Dössinger G, Bet J, Paszkiewicz PJ, Pfeifer L, Bunse M, Uckert W, Holtappels R, Gillert-Marien D, Neuenhahn M, Krackhardt A, Reddehase MJ, Riddell SR, Busch DH.

Sci Transl Med. 2013 Jul 3;5(192):192ra87. doi: 10.1126/scitranslmed.3005958.

33.

T cells expressing a chimeric antigen receptor that binds hepatitis B virus envelope proteins control virus replication in mice.

Krebs K, Böttinger N, Huang LR, Chmielewski M, Arzberger S, Gasteiger G, Jäger C, Schmitt E, Bohne F, Aichler M, Uckert W, Abken H, Heikenwalder M, Knolle P, Protzer U.

Gastroenterology. 2013 Aug;145(2):456-65. doi: 10.1053/j.gastro.2013.04.047. Epub 2013 Apr 30.

34.

MHC multimer-guided and cell culture-independent isolation of functional T cell receptors from single cells facilitates TCR identification for immunotherapy.

Dössinger G, Bunse M, Bet J, Albrecht J, Paszkiewicz PJ, Weißbrich B, Schiedewitz I, Henkel L, Schiemann M, Neuenhahn M, Uckert W, Busch DH.

PLoS One. 2013 Apr 26;8(4):e61384. doi: 10.1371/journal.pone.0061384. Print 2013.

35.

NY-ESO-1 antigen-reactive T cell receptors exhibit diverse therapeutic capability.

Sommermeyer D, Conrad H, Krönig H, Gelfort H, Bernhard H, Uckert W.

Int J Cancer. 2013 Mar 15;132(6):1360-7. doi: 10.1002/ijc.27792. Epub 2012 Sep 14.

36.

T-cell receptor gene transfer exclusively to human CD8(+) cells enhances tumor cell killing.

Zhou Q, Schneider IC, Edes I, Honegger A, Bach P, Schönfeld K, Schambach A, Wels WS, Kneissl S, Uckert W, Buchholz CJ.

Blood. 2012 Nov 22;120(22):4334-42. doi: 10.1182/blood-2012-02-412973. Epub 2012 Aug 16.

37.

Protective capacity of virus-specific T cell receptor-transduced CD8 T cells in vivo.

Mueller K, von Mässenhausen A, Aichele U, Stärck L, Leisegang M, Uckert W, Pircher H.

J Virol. 2012 Oct;86(19):10866-9. doi: 10.1128/JVI.01472-12. Epub 2012 Jul 11.

38.

Human antitumor CD8+ T cells producing Th1 polycytokines show superior antigen sensitivity and tumor recognition.

Wilde S, Sommermeyer D, Leisegang M, Frankenberger B, Mosetter B, Uckert W, Schendel DJ.

J Immunol. 2012 Jul 15;189(2):598-605. doi: 10.4049/jimmunol.1102165. Epub 2012 Jun 11.

39.

TCR-transgenic lymphocytes specific for HMMR/Rhamm limit tumor outgrowth in vivo.

Spranger S, Jeremias I, Wilde S, Leisegang M, Stärck L, Mosetter B, Uckert W, Heemskerk MH, Schendel DJ, Frankenberger B.

Blood. 2012 Apr 12;119(15):3440-9. doi: 10.1182/blood-2011-06-357939. Epub 2012 Feb 27.

40.

The only proposed T-cell epitope derived from the TEL-AML1 translocation is not naturally processed.

Popovic J, Li LP, Kloetzel PM, Leisegang M, Uckert W, Blankenstein T.

Blood. 2011 Jul 28;118(4):946-54. doi: 10.1182/blood-2010-12-325035. Epub 2011 May 25.

41.

Transmitter- and hormone-activated Ca(2+) responses in adult microglia/brain macrophages in situ recorded after viral transduction of a recombinant Ca(2+) sensor.

Seifert S, Pannell M, Uckert W, Färber K, Kettenmann H.

Cell Calcium. 2011 Jun;49(6):365-75. doi: 10.1016/j.ceca.2011.03.005. Epub 2011 May 4.

PMID:
21536328
42.

Interleukin-9 (IL-9) and NPM-ALK each generate mast cell hyperplasia as single 'hit' and cooperate in producing a mastocytosis-like disease in mice.

Merz H, Kaehler C, Hoefig KP, Branke B, Uckert W, Nadrowitz R, Cerny-Reiterer S, Herrmann H, Feller AC, Valent P.

Oncotarget. 2010 Jun;1(2):104-19.

43.

MHC-restricted fratricide of human lymphocytes expressing survivin-specific transgenic T cell receptors.

Leisegang M, Wilde S, Spranger S, Milosevic S, Frankenberger B, Uckert W, Schendel DJ.

J Clin Invest. 2010 Nov;120(11):3869-77. doi: 10.1172/JCI43437. Epub 2010 Oct 11.

44.

Targeting the epidermal growth factor receptor (HER) family by T cell receptor gene-modified T lymphocytes.

Meyerhuber P, Conrad H, Stärck L, Leisegang M, Busch DH, Uckert W, Bernhard H.

J Mol Med (Berl). 2010 Nov;88(11):1113-21. doi: 10.1007/s00109-010-0660-z. Epub 2010 Aug 11.

PMID:
20700725
45.

Do CARs need a driver's license? Adoptive cell therapy with chimeric antigen receptor-redirected T cells has caused serious adverse events.

Büning H, Uckert W, Cichutek K, Hawkins RE, Abken H.

Hum Gene Ther. 2010 Sep;21(9):1039-42. doi: 10.1089/hum.2010.131. No abstract available.

PMID:
20626322
46.

Minimal amino acid exchange in human TCR constant regions fosters improved function of TCR gene-modified T cells.

Sommermeyer D, Uckert W.

J Immunol. 2010 Jun 1;184(11):6223-31. doi: 10.4049/jimmunol.0902055. Epub 2010 May 5.

47.

Lethal graft-versus-host disease in mouse models of T cell receptor gene therapy.

Bendle GM, Linnemann C, Hooijkaas AI, Bies L, de Witte MA, Jorritsma A, Kaiser AD, Pouw N, Debets R, Kieback E, Uckert W, Song JY, Haanen JB, Schumacher TN.

Nat Med. 2010 May;16(5):565-70, 1p following 570. doi: 10.1038/nm.2128. Epub 2010 Apr 18.

PMID:
20400962
48.

T-cell receptor gene-modified T cells with shared renal cell carcinoma specificity for adoptive T-cell therapy.

Leisegang M, Turqueti-Neves A, Engels B, Blankenstein T, Schendel DJ, Uckert W, Noessner E.

Clin Cancer Res. 2010 Apr 15;16(8):2333-43. doi: 10.1158/1078-0432.CCR-09-2897. Epub 2010 Apr 6.

49.

Tumor rejection by local interferon gamma induction in established tumors is associated with blood vessel destruction and necrosis.

Briesemeister D, Sommermeyer D, Loddenkemper C, Loew R, Uckert W, Blankenstein T, Kammertoens T.

Int J Cancer. 2011 Jan 15;128(2):371-8. doi: 10.1002/ijc.25350. Epub 2010 Mar 23.

50.

Enhanced T cell receptor gene therapy for cancer.

Kieback E, Uckert W.

Expert Opin Biol Ther. 2010 May;10(5):749-62. doi: 10.1517/14712591003689998. Review.

PMID:
20201709

Supplemental Content

Loading ...
Support Center